SONN
Sonnet BioTherapeutics
SONN
SONN
Delisted
SONN was delisted on the 2nd of December, 2025.
27 hedge funds and large institutions have $3.53M invested in Sonnet BioTherapeutics in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
5.6% more ownership
Funds ownership: 5.7% → 11.29% (+5.6%)
Holders
27
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$665K | |
| 2 | +$427K | |
| 3 | +$329K | |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$250K |
| 5 |
Goldman Sachs
New York
|
+$245K |
Top Sellers
| 1 | -$166K | |
| 2 | -$28.3K | |
| 3 | -$16.9K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.84K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$7 |
